Synta Pharmaceuticals

Synta Pharmaceuticals Corp., a biopharmaceutical company, is dedicated to discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients suffering from serious illnesses, including cancer and chronic inflammatory diseases. It has established a global partnership with Roche to develop novel CRACM inhibitors, an oral calcium release-activated calcium modulator ion channel inhibitor program currently in the optimal stage for treating autoimmune diseases. The company also holds rights to other drug candidates and programs across various indications and markets, including STA-9090, an Hsp90 inhibitor in development phase 1; elesclomol, an oxidative stress inducer for cancer treatment; and apilimod, an oral IL-12/23 inhibitor in phase 2 for rheumatoid arthritis. Additionally, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent in preclinical development. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.